Search This Blog

Thursday, October 1, 2026

 

Nektar starts third Phase 3 atopic dermatitis trial for rezpegaldesleukin, plans Phase 3 alopecia areata study in 2027

  • Reported new 52-week and off-treatment Phase 2b rezpegaldesleukin durability data in alopecia areata and atopic dermatitis at EADV 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)